Expert US stock analyst coverage consensus and rating distribution analysis to understand market sentiment and Wall Street expectations for specific stocks. We aggregate analyst opinions to provide a consensus view of Wall Street expectations including price targets and ratings. We provide consensus ratings, price target analysis, and analyst sentiment for comprehensive coverage. Understand market expectations with our comprehensive analyst coverage and consensus analysis tools for sentiment investing.
Spyre Therapeutics Inc. (SYRE) is a clinical-stage biotechnology company focused on developing innovative therapies for inflammatory and autoimmune diseases. The stock has demonstrated resilience in recent trading sessions, with shares currently trading near $73.1, reflecting a modest gain of approximately 0.14%. This slight upward movement suggests the stock is maintaining stability within its recent trading range, as investors assess the company's pipeline progress and broader market condition
What would it take for Spyre Therapeutics (SYRE) to double from here? (Technical Strength) 2026-05-08 - Scalping
SYRE - Stock Analysis
3966 Comments
1427 Likes
1
Zani
Active Contributor
2 hours ago
Couldβve made use of this earlier.
π 99
Reply
2
Jamear
Registered User
5 hours ago
Overall market momentum remains steady, with periodic pullbacks providing potential buying opportunities.
π 90
Reply
3
Cordale
Senior Contributor
1 day ago
Such a missed opportunity.
π 73
Reply
4
Caelan
Engaged Reader
1 day ago
Comprehensive US stock investment checklist and decision framework for systematic stock evaluation. Our methodology provides a structured approach to analyzing opportunities and making consistent investment decisions based on proven principles.
π 283
Reply
5
Shikhar
Legendary User
2 days ago
Comprehensive US stock backtesting and historical performance analysis to validate investment strategies before committing capital. We provide extensive historical data that allows you to test any trading idea before risking real money.
π 68
Reply
Disclaimer: Not investment advice. For informational purposes only. Past performance does not guarantee future results. Trading involves substantial risk of loss.